welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
not yet recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

key information

study id #: NCT04281485

condition: Duchenne Muscular Dystrophy

status: not yet recruiting

purpose:

The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year.

intervention: PF-06939926, Placebo

mechanism of action: Gene therapy to introduce a version of dystrophin

results: https://clinicaltrials.gov/ct2/show/results/NCT04281485

last updated: July 19, 2020